High-quality products
Reliable performance
Advances in adeno-associated virus (AAV) -mediated gene therapy are a possibility for commercial production of AAV vectors. Simultaneous efforts are needed to increase the complexity of AAV carrier production techniques and support analysis. In the critical release analysis of clinical gene therapy products, monitoring potentially harmful contaminants is critical to patient safety. A prominent contaminant in many AAV vector preparations is carrier particles lacking genomes, which can significantly increase the dose of AAV capsid proteins and may lead to unintended immune consequences.
High-quality products
Reliable performance
Wide range of applications
For various laboratory needs
Expert support
Professional service team
Fast delivery
Global shipping